Cotinga Pharmaceuticals EV/EBITDA
Qual é o EV/EBITDA de Cotinga Pharmaceuticals?
O EV/EBITDA de Cotinga Pharmaceuticals, Inc. é N/A
Qual é a definição de EV/EBITDA?
EV/EBITDA é o valor da empresa dividido pelo lucro antes de juros, impostos, depreciação e amortização. É uma medida de quão cara é uma ação e é mais frequentemente válida para comparações entre empresas do que da relação entre preço e lucro. Ele mede o preço (na forma de valor da empresa) que um investidor paga em benefício do fluxo de caixa da empresa (na forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de empresas na Setor Health Care em TSXV em comparação com Cotinga Pharmaceuticals
O que Cotinga Pharmaceuticals faz?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Empresas com ev/ebitda semelhantes a Cotinga Pharmaceuticals
- Adrabbit tem EV/EBITDA de N/A
- Chipotle Mexican Grill tem EV/EBITDA de N/A
- Azarga Metals tem EV/EBITDA de N/A
- redT energy plc tem EV/EBITDA de N/A
- Astra tem EV/EBITDA de N/A
- Shield Therapeutics Plc tem EV/EBITDA de N/A
- Cotinga Pharmaceuticals tem EV/EBITDA de N/A
- Cubicfarm Systems Corp tem EV/EBITDA de N/A
- LQwD FinTech tem EV/EBITDA de N/A
- CBK tem EV/EBITDA de N/A
- Rich Goldman tem EV/EBITDA de N/A
- Englobal tem EV/EBITDA de N/A
- Aurelius Minerals tem EV/EBITDA de N/A